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Summory
Rabbit being a common animal modei to evaluate the antithrombot-
ic effect of heparins, our pulpose was to apply the heparin Standard
Independent Unit (SIU) approach to rabbit plasma. To take into account
the specificities of the enzymes we have measured the decay constants
of factor Xa and of thrombin from autologous and heterologous origins,
in presence and in absence of heparin. Different heparins or heparin
fractions with a mean molecular weight from 1.7 to 10.5 kDa were
used.
We found that: a) the decay constants varied strongly between
species and between enzymes; b) the decay constants of thrombin were
always higher than those of factor Xa; c) the specific anti-factor Xa
activity of heparins increased with the molecular weight and was
1.33 times higher when determined with bovine factor Xa than with
rabbit factor Xa; d) the specific antithrombin activity of heparins also
increased with the molecular weight but was similar when determined
with rabbit and human thrombin; e) the specific anti-factor Xa activity
was always lower than the specific antithrombin activity; i) the calibra-
tion of the heparins and heparin fractions against the 4th International
Standard of Heparin expressed in International Units (IU) lead to a
systematic overestimation f the anti-factor Xa activity and to an under-
estimation of the antithrombin activity.
These observations indicate that it may be very imporlant to use the
SIU approach and to know the accurate activities to better understand
the mechanism of the antithrombotic activity of heparins in experimen-
tal models.
Inlroduction
Most animal studies on the antithrombotic effect of heparins use rab-
bit thrombosis models. The antithrombotic action of heparins is medi-
ated by catalysing the inhibition of thrombin, factor Xa and other
clotting factors by antithrombin (AT) (1, 2). So, in the rabbit, heparins
act through the rabbit coagulation system, which is not necessarily
quantitatively identical to that of the human. The results therefore
should be interpreted while keeping possible differences between the
human and the rabbit in mind.
In order to be active, heparin has to contain the specific pentasaccha-
ride sequence that binds to AT (3) (high affinity material; HAM). HAM
molecules with a molecular weight above 5.4 kDa are able to act on
both factor Xa and thrombin inactivation. those with a molecular
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weight below 5.4 kDa are able to catalyse factor Xa inactivation only
(4). This distinguishes ACLM (above critical chain length material)
from BCLM (below critical chain length material). So the specific anti-
factor Xa activity of a heparin is caused by all HAM molecules and the
specific antithrombin activity by its subgroup, the ACLM molecules
only, Unfractionated heparin hardly contains any BCLM but low
molecular weight heparins (LMWHs) do to a varying degree.
A LMWH preparation therefore is always a mixture of ACLM and
BCLM. It is impossible to quantify such a mixture by comparing it to a
standard that contains ACLM only (like the International Standard
Heparin, ISH). When the anti-factor Xa activity is measured, BCLM
counts on an equal basis as the much stronger anticoagulant than
ACLM. When the antithrombin activity is assessed, BCLM is disre-
garded. This is not remedied by the introduction of a LMWH-standard,
as long as the latter standard is itself characterised byconparison to an
UFH standard (5). On top of that, the usual ln vllro comparison of
LMWHs to the ISH, which is canied out in the absence of Ca**, will
overestimate he anti-factor Xa activity of LMWH about wice, due to
the Ca++ dependency of anti-factor Xa activity of large molecular
weight heparins contained in the standard (6).
It therefore was proposed to express anti-factor Xa- and antithrom-
bin activity independent of any standard, but by direct quantitation of
the catalytic effect of heparin on AT-mediated thrombin and factor Xa
breakdown. This led to the definition of a Standard Independent Unit
(SIU) of heparin activity (5). One SIU of anti-factor Xa (or antithrom-
bin) activity of heparin is the amount of heparin that, in normal plasma,
increases the decay constant of factor Xa (or thrombin) by 1 min r per
pM of plasmatic AT.
Another source of confusion in the heparin field is the expression
of heparin concentration. The weight of a heparin preparation is not
related to the number of active molecules because: a) there is a large
number of inactive heparin molecules present and b) the numbet avet-
age molecular weight of the active fraction is unknown. This however
can be circumvented because the molarity of a solution of AT binding
heparin can be determined by fluorescent titration (7).
The combination of expressing the activity of a heparin in absolute
terms (in SIU) and the concentration i  molar terms allows, for the first
time, to characterise the specific activity of a heparin, standard- and
method-independently, as SIU per mole.
Although expressed in absolute tems, the specific activity of a hep-
arin remains dependent upon the reaction conditions, temperature, pH,
ionic strength and the nature of the other eactants: thrombin, factor Xa
and antitlrombin. The determination should therefore be done under
conditions that are as near as possible to invivo ctrcwstances. This not
only means that it should be determined inplasma t a normal Ca++ con-
centration but also in plasma of the relevant species.
The aim ofthis study was to apply the SIU approach to rabbit plas-
ma. So we determined the specific anti-factor Xa- and antithrombin
activities in SIU of a series of heparin preparations under conditions
prevailing in the rabbit, i. e. in rabbit plasma with autologous factor Xa
and thrombin.
Moleriols ond Mefhods
Preparation of Plasmas
Biood from 12 New Zealand male rabbits (2-3 kg) was collected on 0.129 M
trisodium citrate (9 parts of blood to 1 part of citrate solution) via the left
carotid artery. Platelet poor plasma (PPP) was obtained after two centrifuga-
tions at 15o C, for 15 min at 3000 X g, and a third centrifugation at 4" C, for
I h at 20,000 X g. These PPP were pooled and stored at -80' C
Defibrinated plasma was obtained by mixing an aliquot of plasma with
0 25 IU/ml of ancrod, letting a clot form for 10 min at 37" C. The resultant clot
was squeezed and then discarded by winding it on a small plastrc spatula.
Human PPP from 10 healthy donors was prepared analogously to rabbit
PPP
Heparins
The 4th Intemational Standard of Heparin (4th ISH) and first International
Standard of Low Molecular Weight Heparin (lst ISLMWH) were a kind gift of
Dr. T. W. Banowcliffe from National Institute of Biological Standards and
Control (Hertfordshire, UK).
The CY 216 and its ACLM and BCLM fractions previously used in refer-
ence (8) (batch XH 716 C, P 2016 XH andP 2017 XH respectively) and the
synthetic pentasaccharide (PS) that represents he antithrombin (AT) binding
site of heparin (3) were supplied by Sanofi-Recherche (Gentilly, France)
The Logiparin (batch LMW 9101) was obtained from Novo Nordisk
(Copenhagen, Denmark)
The Fragmin (batch 45314-51) was obtained from KabiPharmacia (Stock-
holm. Sweden).
The molar concentrations of the heparin species with high affinity for AT
(HAM) in each preparation were determined as described in (7).
The percentage of the heparin species with a molecular weight above
5.4 kDa (ACLM) in each preparation was determined by the manufacturers.
Table 1 summarizes the molecular weight (MW), the HAM and the ACLM
in each heparin preparations.
The specific antithrombin and anti-factor Xa activities expressed in
IU mgi were determined as previously described (9).
Reagents
The chromogenic substrates for thombin (5-2238) and for factor Xa
(5-2337) were obtained from Cluomogenix (Mcilndal, Sweden)
Buffer A: 20 mM Hepes, 150 mM NaCl, 0.5 mg/ml bovine serum albumin,
pH 7 35 Buffer B: 20 mM Hepes, 150 mM NaCl, 20 mM EDTA, 0.5 mg/ml
bovine serum albumin, pH 7.90 Buffer C: 20 mM Hepes, 220 mM NaC1,
20 mM EDTA,0.5 mg/ml bovine serum albumin, pH 7.90.
Ancrod was a kind gift of National Institute of Biological Standards and
Control (Herfordshire, UK) and dissolved according to the instructions of the
manufacturer.
Recombinant hirudin (r-hirudin) was a kind gift of Dr. R B. Wallis
(Ciba-Geigy, Horsham, UK)
Recombinant tissue factor (rTF) was obtained from Baxter Diagnostics
(Switzerland) Before use in thrombin generation test it was diluted with
buffer A containing 0.1 M Ca+* so as to clot a mixture of pooled human PPP in
34-35 s (30 pl of rTF, 30 pl of buffer A and 120 pl of PPP).
Human thrombin was prepared from euglobulin fraction obtained from
defibrinated pooled human PPP by acid precipitation (pH 5.2) at a low ionic
strenght as previously described (10). The precipitate was collected by centrif-
ugation and dissolved in half the initial plasma volume in buffer A containing
21.6 mM trisodium citrate. In order to obtain ttrombin, thrombin generation
was triggered by adding 0.25 vol of diluted rTF to 1 vo1 of euglobulin fraction.
Human, bovine and rabbit clotting factors were prepared according to tech-
niques described in (1 1) and (12).
Determination of the Decay Conrtafis of Thrombin
A mixture of 80 pl of defibrinated rabbit plasma nd 20 pl of buffer A with
or without heparin was prewarmed for 5 min at 3'7' C. Then 20 pl of human,
bovine or rabbit hrombin were added to obtain a final concentration of 70 nM.
At timed intervals (3-5 s), a 10 pl aliquot was sampled into a disposable plastic
cuvette containing 490 p1 of a 200 pM of 5-2238 in buffer B The sampling
was done with a pushbutton equipped pipette that recorded the moment of sam-
pling on a personal computer. After about 3 min the amidolytic reaction was
stopped by adding 300 pl of 1 M citric acid. The moment of stopping was also
recorded automatically Optical densities were read at 405 nm in a dual wave-
length (405-500 nm) dedicated instrument constructed in our workshop The
concentrations of thrombin were read from the AOD/min values via a propor-
tionality constant obtained with active site titrated tluombin.
The amidolytic activities (C,) were fitted to the tluee parameters curve
Ct = C- + (C"-CJ ' e kt, where k = ka"., Co is the initial amidolytic activity and
C- is the residual, steady endJevel activity due to the or-macroglobulin-throm-
bin (orM-T) complex The decay constant (kdec) was the sum of the AT depen-
dent parl (k1) and the or-macroglobulin dependent pafi (k2). It was shown that
k1 was linearly dependent upon the heparin concentration, whereas k2 was not
dependent on heparin (13)
Determination of the Decay Constants of Factor Xa
A mixture of 80 pl of defibrinated rabbit plasma, 7 pl of r-hirudin (35 pM)
and 6 pl of buffer A with or without heparin was prewarmed for 270 s at 37" C.
Then 7 pl of CaCl, (0.2 M) were added and then 30 s later 20 pl of human;
bovine or rabbit factor Xa so as to obtain a final concentration of 170 nM. At
timed intervals (4-6 9, a 10 pl aliquot was sampled into a disposable plastic
cuvette containing 490 pl of a 200 pM ofS-233T in buffer C. The disappear-
ance of factor Xa was then measured as described above for thrombin and the
decay constants were calculated analogously to those of thrombm.
Calculation of Specific Activities
One SIU of anti-factor Xa activity (SIU Xa) or of antitluombin activity
(SIU IIa) is defined as the amount of heparin that, in normal plasma, increases
the decay constant of factor Xa (or thrombin) by 1 minr per pM of plasmatic
AT. It therefore is calculated by devision of the increase of the relevant decay
constant by AT content of the plasma.
Table I Moleclrtlar properties of
different heparin preparations Heparins MW HAM
kDa pM/Ug
ACLM
4rh tsH 10 50 0.058
Logiparin 6.90 0 040
Fragmin 6.20 0.082
1d |SLMWH 5.39 0 098
cY 216 5.09 0 038
100
75
55 1
61 .5
40
100
0
0
ACLM
BCLM
PS
6.71
3.63
1.70
0 052
o o24
0.589
ACLM and BCLM are the fractions ol
CY 216 prepared by gel filtration
J I J
Table 2 Half-life times and decay constants of factor Xa and thrombin of dif-
ferent species in rabbit and human plasma
rabbit plasma human plasma
In pooled rabbit plasma the functional AT concentration was found
to be 2.2'l t 0.14 u.M (n = 3) which was similar to that in human
plasma (2.24 t 0.11 pM) (14). Identical results were obtained using
rabbit and human thrombin.
AT Specificity for Thrombin and Factor Xa
A marked species pecificity was observed in the interaction of clot-
ting factors with AT. Table 2 shows that the decay constants of factor
Xa and thrombin differ according to the source of clotting factors and
of the plasma used. In rabbit plasma the decay constants of human and
bovine factor Xa were respectively 1.25 times lower and 1.23 times
higher than that of rabbit factor Xa and the decay constants of human
and bovine thrombin were respectively |.72 and 1.48 times lower than
that of rabbit hrombin. In human plasma, the decay constants of human
and bovine factor Xa were respectively 2.58 and 1.29 times lower than
that of rabbit factor Xa and the decay constants of human and bovine
thrombin were respectively 1.06 and 1.41 times lower than that of
rabbit tlrombin. The decay constants of rabbit factor Xa and human
thrombin were similar in rabbit and human plasma but those of the four
other preparations were different.
Moreover, the decay constants of thrombin were always higher than
those of factor Xa, both in rabbit and human plasma.
The Specific Antithrombin Activities of Dffirent Heparins
The specific activity of a heparin is defined as the increase of the
decay constant of thrombin in plasma per amount of heparin and per
u,M of AT. For a series of different heparins, the pseudo-first order
decay constants of exogenous thrombin (rabbit and human) were deter-
mined as a function of the concentration of the heparins. The activity,
if present, always increased linearly with the concentration of the hep-
arin. Table 3 summarizes the specific antithrombin activities found in
rabbit plasma.
We found that the specific antithrombin activity measured in rabbit
plasma was independent of the type of thrombin used. The ratio of the
specific antithrombin activities determined with human thrombin to the
ones determined with rabbit thrombin was 1.02 t 0.09 (mean t SD).
The Specffic Anti-factor Xa Activities of Dffirent Heparins
Table 4 summarizes the specific anti-factor Xa activities, defined
analogously tothe specific antithrombin activity above, found in rabbit
plasma. For a series of different heparins, the pseudo-first order decay
constants of exogenous factor Xa (rabbit and bovine) were determined
for increasing concentrations of the heparins as in the previous para-
graph. Again the constants always increased linearly with the concen-
tration of the heparin.
We found that for each heparin, except for CY 216, the specific anti-
factor Xa activity in rabbit plasma was 1.33 t 0.1 1 (mean t SD) times
higher with bovine factor Xa than with rabbit factor Xa.
The specific anti-factor Xa activity of heparins in rabbit plasma
increases as a function of the molecular weight, most significantly at
molecular weights above 6.2 kDa.
Calculation Coefficients oShift from IU to SIU; the Ratios of Specific
Antifactor Xa to Antithrombin Activities of Heparins
In Table 5 we give the potency of heparins in IU and SIU and the
calculation coefficients to shift between the two types of unit. When
.1t2
(s)
kdec
(min 1)
kdec
(mini)
tttz
(s)
rabbit factor Xa
human faclor Xa
bovine factor Xa
31 5t1.8 1.32x0.O7 30.4*1.1
39.412.4 1 06+0.07 79 0*3 3
26.0+3.3 1.62t0.18 392!22
1.37t0.05
0.53t0.02
1 06t0.06
rabbit thrombin
human thrombin
bovine thrombin
9.6*0 5
1 6 5 + 1  0
142+ {5
4 35tO24 15 9+1.1 2.63+0.17
2.53+0 16 16.710.4 2 49+0.06
2.93ro 11 22.2t1 1 1 8710.09
kdec=ln 2/t1/2 with t1/2 expressed in minutes
Resulls are given as meanrSD of at least 3 experiments.
Resulls
Determination ofFunctional AT Concentration i Plasma
Because heparin activity is proportional to the AT concentration of
the medium, the SIU must be expressed per pM of AT in the plasma
(5). To determine the AT content of the plasma we titrated the unknown
amount of AT with a known excess amount of thrombin and deter-
mined the residual thrombin activity. In a plastic spectrophotometer
cuvette 100 pl of a suitable dilution of the plasma (1:100 to 1:400) in
buffer B containing 2 lUlml unfractionated heparin were incubated
with 100 u,l of a 20 nM thrombin solution at3l' C during 40 min. Then
300 pl of 330 pM 5-2238 in buffer B were added, and the amidolytic
activity of the residual thrombin was measured at 405 nm in a spectro-
photometer at3l" C. This activity was converted into nM thrombin via
a reference curve obtained with active site titrated thrombin. The AT
concentration was calculated as the difference between the initial
thrombin concentration added and the residual thrombin activity found.
Table 3 Specific antithrombin activities of different heparin preparations i
rabbit plasma determined with rabbit (R) or human (H) thrombm
SIU  l l a
Heparins min'1/pg/ml
R H
minj/pM HAM min l/pM ACL-HAM
R H R H
4M ISH
Logiparin
Fragmin
lSI  ISLMWH
cY 216
7 52 7.32
2.48 2.42
13.88 15 90 239.31 274.14 239.31 274.14
5.40 5.43 135.00 135 75 180.00 181 00
10.34 922 126 10 11244 22A.A5 20406
76.73 74 69 127 .77 121.45
65.26 63.68 163.16 159.21
1 94 8 t 220 38 .1 94 81 220.38
PS
ACLM 10 .13  11 .46
BCLM 0.15 0.08 6.25
The values reoorted are the mean ol at least 3 determinations with
standard eviations of approximately 9%.
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expressed in SIU, the ratios of the specific anti-factor Xa activities to
those of thrombin (min l/pg/ml) as determined with rabbit factors wsre
calculated for each heparin preparation. The ratio was 0.59 for 4th ISH
and the mean ratio was 0,24 (range from 0.17 to 0.36) for the LMWHs,
i.e. almost 2.5 times lower; so the specific antithrombin activity was
always higher than the specific anti-factor Xa activity and the ratio
decreased with molecular weisht.
Discussion
In this study, it was our aim to investigate the antithrombin system
in the rabbit, the most commonly used animal in thrombosis models.
Unfractionated and various low molecular weight heparin preparations
were used. Because of species-dependent variation in the behaviour
of the enzymes, the relative units have a different meaning in rabbit
plasma nd in human plasma. Differences can be easily missed if the
activities are expressed relative to a standard. if the rabbit system
reacts [0 the standard and to the heparin in a similar manner. E. g. if in
rabbit plasma the specific anti-factor Xa activity of a heparin - but
not its antithrombin activity - would always be three times higher than
in the human, both with the standard and with the heparin under in-
vesti,ration, than this would go unobserved if activities are expressed
relative to that standard. Yet the mechanism ofaction of the drug might
be mediated via factor Xa in the rabbit and not in the human. Also
the molecular weight dependence of heparin activity could be dif-
ferent in the rabbit and in the human, if their AT molecules would
be sufficiently different. Therefore, species differences hould be
obligatorily expressed in terms of absolute catalytic activity of heparins
(5 ) .
For these reasons, we determined the specific anti-factor Xa and
antithrombin activities of a series of heparins in a homologous rabbit
system in standard independent terms. We also included experiments
with heterologous material because bovine factor Xa and human tlirom-
bin are more readily available than rabbit products are and therefore are
often used in practice.
Table 2 shows that there are impofiant species differences in the ab-
solute decay velocities in the human and in the rabbit, the latter being
on the mean about 1.5 times faster.
Human thrombin decays with normal, low velocity in rabbit plasma,
which excludes the possibility that the high reactivity of the rabbit
thrombin-AT interaction might be due to the presence of endogenous
ACLM activity in the rabbit plasma. We must conclude that there are
important species differences between the rabbit and the human, and
that it seems notjustified to extrapolate data obtained in a rabbit system
to a human system.
By definition, in international units, the ratio of the anti-factor Xa to
antithrombin activities is i for the 4th ISH It is higher than 1 for low
molecular weight heparins, which suggests that LMWHs would in-
crease more the AT effect on factor Xa than on thrombin. However,
since thrombin is much more sensitive to the heparin-AT complex than
factor Xa is, the ratio of absolute anti-factor Xa/antithrombin activities
is always maller than 1 (Table 5), varying from 0.59 for the 4th ISH to
0.24 on average for LMWHs.
Therefore, in rabbit plasma, the 4th ISH shows a slightly higher anti-
thrombin activity than the anti-factor Xa and the LMWHs present a
very high antithrombin activity with regard to their anti-factor Xa activ-
ity. Consequently, when rabbit thrombosis model experiments were
designed on the basis of anti-factor Xa units, a (very) high amount of
antithrombin units accompanies this activity, conffary to what we are
induced to think when we use international units (15).
Table 4 Speclfi,c anti-factor Xa activities of different heparin preparations in
rabbit plasma determined with rabbit (R) or bovine (B) factor Xa
SIU Xa
Heparins min-1/pg/ml
R B
min-1/pM HAM
R B
4rh lsH
Logiparin
Fragmin
BCLM
PS
8.21 10.88
1 .48  1 .93
1.BB 2.42
0.36 0.56
7 .53 10.06
141 .55 187.59
37.00 48.25
22.93 29.51
18.67 24.90
23.68 23.95
32.69 43.65
15.00 23.33
12 .78  17 .08
1St ISLMWH 1.83 2.44
CY 216 0.90 0.91
ACLM 1.70 2.27
The values reported are the mean of at least 3
determinations with standard deviations of approximately 6"/"-
Table 5 Calcdation coefficients o shift from IU to SIU and anti-factor
Xa/antithrombin ratios in rabbit plasma
Heparins Antijactor Xa activity
IU SIU SIU/IU
Antithrombinactivity Ratioaxa/alla
IU SIU SIU/IU IU SIU
4rh lsH
Logiparin
Fragmin
1 i l  ISLMWH
C Y  2 1 6
1 9 4  I  2 1
g 5  I 4 8
152 1 88
168 1  83
6 5  0 9 0
120 1 70
o o42
0  0 1 7
0  0 1 2
0 0 1  1
0  014
0,0.14
0 5 9
0 2 7
0 1 8
0 2 4
0 3 6
0 1 7
(2 4l
194
50
6 6 5
6 6 5
26
100
0 2
1388  0072  1  00
5 4 0  0 1 0 8  1 7 0
'10 34 0 155 2 29
7  52  0  113  253
248 0 095 250
1 0 1 3  0 1 0 1  1 2 0
o  15  075  (190 )
ACLM
BCLI\4
PS
38  0s6  0009
350 7 53 0022
The activities are expressed in lU/mg for International Unit (lU) and minr/pg/ml
lor Standard Independent Unit (SlU) Values given in brackets are not relevant,
BCLM being almost devoid ol antFthrombin activity
The specific anti-factor Xa activities of different heparin prepara-
tions in rabbit plasma have also been determined with bovine factor Xa
and, except for CY 2 1 6, all of them have been found about 1.33 times
higher than with rabbit factor Xa (Table 4). So if the more convenient
commercial bovine factor Xa preparation is used, one has to apply a
conversion coefficient of 1.33 to the value found with factor Xa in
order to obtain the accurate specific anti-factor Xa activity in rabbit
plasma,
3 1 5
With human and rabbit hrombin preparations, the specific activities
obtained were similar (Table 3). Therefore it is possible to use directly
the values found with human thrombin in rabbit plasma.
Like in human plasma (data not published) we observed in rabbit
plasma n increase of the specific activities as a function of the molec-
ular weight of heparin (Tables 3 and 4); for anti-factor Xa activity the
effect was more pronounced above 6.2 kDa while the antithrombin
activity was increased according to the molecular weight.
This study confirms that the specific anti-factor Xa and antithrombin
activities of different heparin preparations may be different according
to the species tudied, the source of clotting factors used and the defini-
tion of units, IU or SIU. Consequently it could be very important to
re-evaluate he antithrombotic potencies of heparins using the absolute
activities determined in systems of the relevant species.
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